Psychedelic study to test if 'Trip' or brain chemistry boosts mood
NCT ID NCT07360301
First seen Jan 23, 2026 · Last updated Jun 19, 2026 · Updated 23 times
Summary
This study will give psilocybin to 120 healthy adults with low well-being, either while awake or asleep, to see if the psychedelic experience is needed for mood benefits. Participants will also receive a placebo or clonidine for comparison. The goal is to understand how psilocybin works, not to treat a disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WELL-BEING, PSYCHOLOGICAL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Wisconsin
Madison, Wisconsin, 53792, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
psilocybin
What this could lead to
If successful, this study could help explain whether the psychedelic experience itself or direct brain effects improve well-being, pointing toward better mental health treatments.
What could go wrong
This is an early Phase 1 study with only 120 participants, so results may not apply broadly. The psychedelic experience can be intense and unpredictable, and the study hasn't started recruiting yet.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.